The Food and Drug Administration this week approved two abbreviated new drug applications expected to alleviate shortages and help during the COVID-19 emergency.

Dexmedetomidine hydrochloride 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, and sedation of non-intubated patients prior to and/or during surgical and other procedures.

Succinylcholine chloride injection USP 200 mg/10 mL is indicated for general anesthesia, and to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services this week released updated fact sheets for hospitals and other types of Medicare and Medicaid providers…
Headline
Health care providers who received Provider Relief Fund and/or American Rescue Plan Rural payments exceeding $10,000 total between July 1 and Dec. 31, 2021,…
Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…
Headline
As the Congressional Telehealth Caucus considers updates to legislation that would permanently remove all geographic restrictions on Medicare telehealth…
Headline
The Biden Administration plans to end on May 11 the COVID-19 national and public health emergencies declared in 2020, according to a policy statement …
Headline
The Centers for Medicare & Medicaid Services Friday released additional guidance on changes to the Medicaid continuous enrollment requirement under…